Embed Size (px)
Citation preview
GLOBAL INDUSTRY INSIGHT: Hospital Infection Therapeutics Market Size, Share, Development,
Growth and Demand Forecast to 2020
Global Hospital Infection Therapeutics Market Size, Share,
Development, Growth and Demand Forecast to 2020
The hospital infection therapeutics market is increasing at a significant rate, due to high susceptibility of neonatal
population in healthcare setting and high occurrence of numerous hospital infections. Increasing incidences of
hospital infections, high number of pipeline drug molecules for specific treatment of healthcare associated
infections and high unaddressed needs in most of the countries are some of the factors providing ample
opportunities for the hospital infection therapeutics market to grow in the coming years.
North America leads the hospital infection therapeutics market followed by Europe. The North America hospital
infection therapeutics market leads, due to improved healthcare awareness, high ratio of hospitals as compared
to population of the region, increasing count of multi drug resistant microbial pathogens and increase in aging
population of the region. Asia-Pacific is growing with an exponential rate, due to increased incidences of hospital
infections and high demands of therapeutic drugs in the emerging countries such India and China.
Explore more about Hospital Infection Therapeutics Market: https://www.psmarketresearch.com/market-
analysis/hospital-infection-therapeutics-market
Hospital acquired infections are caused produced by viral pathogens, fungal and bacterial. Most of the hospital
infections crop up from intensive care units. Varied range of hospital infections are being treated by various
antimicrobial drugs. The patients staying in the hospitals develop several infections during their treatment. . The
infections are known as hospital-acquired infections or hospital infections. The hospital acquired infections spread
in the hospitals, rehabilitation centers, outpatient surgery centers, nursing homes and dialysis centers.
Some of the pipeline drugs available in the market for hospital acquired infections are MK-3415A, Amikacin
Inhale, Oritavancin, Surotomycin, Ceftolozane, Dalvance, Plazomicin, Eravacycline, Tedizolid, Delafloxacin, and
CAZ AVI. In 2011, according to the centers for disease control and prevention, around 1.6 million hospital
acquired infections have been reported from all types of bacteria in US every year. Additionally, in 2013 about 4
million patients were identified with hospital acquired infections in Europe.
Lack of skilled nursing staff in underdeveloped and developing economies is increasing the incidences of hospital-
acquired infections, which in turn is driving the growth of hospital infection therapeutics market. The increasing
number of multi drug resistant bacterial strains are presently making antibacterial drugs obsolete available. Also
the increasing hospital surveillance and infection control programs in developed countries has lead to a decline in
number of hospital infections. All these factors are responsible for restraining the growth of hospital infection
therapeutics market.
The hospital infection therapeutics market can be categorized on the basis of drug type into, antifungal drugs,
antibacterial drugs and antiviral drugs. Antibacterial drug leads the global hospital infection therapeutics market
© P&S Market Research. All rights reserved 2
Global Hospital Infection Therapeutics Market Size, Share,
Development, Growth and Demand Forecast to 2020
and is also expected to grow at the highest rate in coming years among the drug types in hospital infection
therapeutics market.
On the basis of infection types, the hospital infection therapeutics market can be categorized into hospital
acquired pneumonia, urinary tract infections, bloodstream infections, surgical site infections and gastrointestinal
disorders. Hospital acquired pneumonia leads the global hospital infection therapeutics market, under the types of
infection categories. While urinary tract infections are expected to grow at an exponential rate in the coming
years.
Request Table of Contents: https://www.psmarketresearch.com/enquiry-form.php?enqid=268&title=TOC
Some of the competitors in the hospital infection therapeutics market are: Cubist Pharmaceuticals, Inc., Actavis
PLC, Johnson & Johnson Services, Inc., Bayer AG, GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Merck
& Co., Inc., AstraZeneca PLC, Pfizer, Inc. and Sanofi.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for
various geographies around the globe. We provide market research reports, industry forecasting reports,
business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate
forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through
their interaction with leading companies of the concerned domain. We help our clients with B2B market research
and assist them in identifying various windows of opportunity, and framing informed and customized business
expansion strategies in different regions.
Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com
© P&S Market Research. All rights reserved 3
